Compare Fubotv Inc (FUBO) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs 10X Genomics Inc — how do they compare? Fubotv Inc trades at $8.92 (market cap $1.02B), while 10X Genomics Inc trades at $80.87 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 9.9× Fubotv Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, Fubotv Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fubotv Inc for 35 Days and 10X Genomics Inc for 91 Days on average.
| FUBO | TXG | |
|---|---|---|
Market Cap | $1.02B | $10.07B |
Volume | 978,631 | 5,657,286 |
Sector | Media | Health |
52-Week High | $48.96 | $97.74 |
52-Week Low | $8.09 | $11.48 |
Typical Hold Time | 35 Days | 91 Days |
Enterprise Value | $1.19B | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO trades at $8.84, down 4.43% today, with bearish technical signals from moving averages but neutral oscillators. The company shows improving fundamentals with revenue growth to $1.62B in 2024 and a projected net profit of $123M in 2025. Recent developments include new sports streaming agreements with NHL and TBL Team Boxing League, while analyst consensus remains mixed with 47% buy ratings and a $63.38 price target.
FUBO presents a turnaround story with improving profitability metrics and strategic content partnerships driving growth potential. However, risks include persistent negative cash flow, high debt levels, and intense streaming competition. The stock's current valuation appears attractive with P/E of 2.43 and P/S of 0.19, but execution risks remain significant for investors.
10x Genomics (TXG) trades at $82.37, up 8.24% over 24 hours, with a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $43.54M in 2025, but revenue grew to $642.82M, and it has beaten EPS estimates for three consecutive quarters. Recent news highlights strong demand for its Atera platform and a patent victory, though profitability remains a challenge.
The outlook is cautiously optimistic, with growth potential from new product launches and spatial biology demand, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target is $74.30, below the current price, suggesting limited near-term upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
